Jason Hoitt

Corporate Officer/Principal at STOKE THERAPEUTICS, INC.

46 year

Health Technology

Consumer Services

Profile

Jason Hoitt is currently the Chief Commercial Officer at Stoke Therapeutics, Inc. He previously held positions as the Head-US Sales at Sarepta Therapeutics, Inc. from 2013 to 2017, Vice President & Head-US Sales at Insmed, Inc. in 2017 to 2018, Chief Commercial Officer at Dova Pharmaceuticals, Inc. from 2018 to 2019, and Chief Commercial Officer at Provention Bio, Inc. from 2020 to 2023.
Mr. Hoitt obtained his undergraduate degree from the College of the Holy Cross (Massachusetts) in 1999.

Jason Hoitt active positions

Companies	Position	Start
STOKE THERAPEUTICS, INC.	Corporate Officer/Principal	14/04/2024

All active positions of Jason Hoitt

Former positions of Jason Hoitt

Companies	Position	End
PROVENTION BIO, INC.	Corporate Officer/Principal	31/05/2023
DOVA PHARMACEUTICALS, INC.	Corporate Officer/Principal	11/11/2019
INSMED INCORPORATED	Sales & Marketing	-
SAREPTA THERAPEUTICS, INC.	Sales & Marketing	30/04/2017

See the detail of Jason Hoitt's experience

Training of Jason Hoitt

College of the Holy Cross (Massachusetts)

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jason Hoitt's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	3
INSMED INCORPORATED	Health Technology
SAREPTA THERAPEUTICS, INC.	Health Technology
STOKE THERAPEUTICS, INC.	Health Technology

Private companies	2
Dova Pharmaceuticals, Inc. Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC.	Health Technology
Provention Bio, Inc. Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.	Health Technology